肿瘤药学2019，Vol.9Issue(2)：238-241,4.DOI:10.3969/j.issn.2095-1264.2019.02.12
阿帕替尼联合紫杉醇在肺癌患者中的疗效分析
Efficacy Analysis of Apatinib Combined with Paclitaxel for Lung Cancer Patients
摘要
Abstract
Objective To explore the efficacy of apatinib combined with paclitaxel in patients with lung cancer and the influence on pulmonary function after treatment. Methods A total of 120 cases of lung cancer treated in our hospital were divided into two groups ac-cording to the different treatment methods. Patients in control group were treated with paclitaxel, and those in observation group were treated with apatinib and paclitaxel. Detect the cytokeratin 19 fragment (CYFRA21-1), Carcinoembryonic antigen (CEA), matrix metallo-proteinase 9 (MMP-9) and vascular endothelial growth factor (VEGF) levels, and compare the therapeutic effect and prognosis between the two groups. Results The therapeutic effective rate of the observation group was significantly higher than that of the control group (P<0.05). The incidence of the adverse reactions of the observation group were lower than those of the control group (P<0.05). After treatment, the levels of CYFRA21-1, CEA, MMP-9 and VEGF in the observation group were significantly lower than those of the control group (P<0.05). Conclusion The combined use of apatinib and paclitaxel for lung cancer patients has achieved good therapeutic effect, high safety and less adverse reactions. It is worthy of further popularization and application in clinic.关键词
阿帕替尼联合紫杉醇/肺癌/疗效观察/对肺功能的影响Key words
Apatinib combined paclitaxel/Lung cancer/Observation of curative effect/Effects on lung function分类
医药卫生引用本文复制引用
LIU Dongli,GAO Yafeng,GAO Fangfang,WANG Mingming,LI Haitao..阿帕替尼联合紫杉醇在肺癌患者中的疗效分析[J].肿瘤药学,2019,9(2):238-241,4.基金项目
国家自然科学基金(81372519). （81372519）
